Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$97.03
+3.8%
$94.34
$79.52
$124.00
$24.53B1.361.06 million shs628,684 shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$290.66
+0.0%
$301.92
$239.25
$385.22
$31.89B0.5251,425 shs89,852 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$156.33
+1.1%
$128.27
$34.00
$156.81
$33.24B1.413.31 million shs2.18 million shs
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$106.91
$106.65
$60.50
$106.93
$9.21B0.052.58 million shsN/A
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
+0.47%+2.76%-8.45%-15.23%-4.19%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
-3.14%-6.15%-2.54%-8.33%+20.87%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+1.07%+0.59%+6.77%+51.57%+309.83%
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
0.00%0.00%0.00%0.00%+44.61%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$97.03
+3.8%
$94.34
$79.52
$124.00
$24.53B1.361.06 million shs628,684 shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$290.66
+0.0%
$301.92
$239.25
$385.22
$31.89B0.5251,425 shs89,852 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$156.33
+1.1%
$128.27
$34.00
$156.81
$33.24B1.413.31 million shs2.18 million shs
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$106.91
$106.65
$60.50
$106.93
$9.21B0.052.58 million shsN/A
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
+0.47%+2.76%-8.45%-15.23%-4.19%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
-3.14%-6.15%-2.54%-8.33%+20.87%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+1.07%+0.59%+6.77%+51.57%+309.83%
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
0.00%0.00%0.00%0.00%+44.61%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.74
Moderate Buy$129.5633.53% Upside
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
2.80
Moderate Buy$389.1533.89% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
3.00
Buy$111.35-28.77% Downside
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
2.00
Hold$121.7513.88% Upside

Current Analyst Ratings Breakdown

Latest VRNA, ONC, RVMD, and BNTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
UpgradeNeutralBuy$117.00 ➝ $135.00
5/21/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Initiated CoverageMarket Perform$151.00
5/21/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Initiated CoverageMarket Perform$96.00
5/21/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
UpgradeHold
5/21/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
UpgradeHold
5/18/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Initiated CoverageBuy$179.00
5/15/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Boost Price TargetOutperform$364.00 ➝ $367.00
5/12/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Lower Price TargetBuy$155.00 ➝ $140.00
5/7/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Reiterated RatingOverweight$395.00
5/7/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Boost Price TargetBuy$410.00 ➝ $420.00
5/7/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Boost Price TargetBuy$205.00
(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$3.25B7.56$1.39 per share69.66$86.54 per share1.12
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$5.34B5.97$3.79 per share76.76$43.39 per share6.70
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M2,870.14N/AN/A$7.06 per share22.14
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
$42.28M217.94N/AN/A$2.56 per share41.76
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$1.29B-$5.88N/AN/AN/A-44.39%-5.30%-4.62%8/3/2026 (Estimated)
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$286.93M$4.4765.0228.03N/A8.94%12.06%6.69%N/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.13B-$7.07N/AN/AN/AN/A-83.22%-59.06%8/5/2026 (Estimated)
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
-$173.42M-$0.99N/A3,563.67N/A-36.62%-21.12%-9.07%N/A

Latest VRNA, ONC, RVMD, and BNTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2026Q1 2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.83-$2.29-$0.46-$2.29$2.43 millionN/A
5/4/2026Q1 2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$2.52-$2.2570+$0.2630-$2.43$207.42 million$136.71 million
4/1/2026Q1 2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
N/A$0.25N/A$1.95N/A$1.51 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/AN/AN/AN/AN/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.01
8.80
8.74
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
0.20
3.64
3.27
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.19
6.80
6.80
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
0.87
10.71
10.54

Institutional Ownership

CompanyInstitutional Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
15.52%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
48.55%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
85.88%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
7,807252.88 million204.33 millionOptionable
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
12,000109.72 million102.93 millionN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
250212.60 million195.16 millionOptionable
Verona Pharma PLC American Depositary Share stock logo
VRNA
Verona Pharma PLC American Depositary Share
3086.19 million82.06 millionOptionable

Recent News About These Companies

Verona Pharma Shareholders Approve Merck Acquisition
Here’s What Lifted Verona Pharma (VRNA) in Q2

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BioNTech stock logo

BioNTech NASDAQ:BNTX

$97.03 +3.59 (+3.84%)
As of 02:10 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

BeOne Medicines stock logo

BeOne Medicines NASDAQ:ONC

$290.66 +0.08 (+0.03%)
As of 02:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$156.33 +1.70 (+1.10%)
As of 02:10 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Verona Pharma PLC American Depositary Share stock logo

Verona Pharma PLC American Depositary Share NASDAQ:VRNA

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.